MaaT Pharma (MAAT.PA)

Executive Summary

MaaT Pharma is a clinical-stage biotechnology company pioneering microbiome-based therapies to restore gut symbiosis in cancer patients, particularly those with severe hematological malignancies. Its lead candidate, MaaT013, is a full-ecosystem, off-the-shelf microbiome therapy in Phase 3 for steroid-refractory acute graft-versus-host disease (SR-aGvHD), with potential to address high unmet need. The company also advances MaaT033 for acute myeloid leukemia (AML) in a Phase 2b trial and MaaT034 for solid tumors in early development. Recent data from MaaT013 have shown promising survival benefits, and the company has engaged with regulatory authorities for potential accelerated approval pathways. With a strong intellectual property portfolio and manufacturing capabilities, MaaT Pharma is positioned to lead in the microbiome-oncology space. Financially, the company is publicly traded on Euronext Paris (MAAT.PA) with a market cap around €120 million, and it has sufficient cash runway into 2027 based on recent fundraising.

Upcoming Catalysts (preview)

• Q3 2026MaaT013 Phase 3 top-line results in SR-aGvHD65% success
• Q4 2026Regulatory submission for MaaT013 in EU under PRIME scheme55% success
• H1 2027MaaT033 Phase 2b interim data in AML50% success